ProPhase Labs to Host Third Quarter 2021 Financial Results Conference Call on Friday, November 12, 2021 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, Nov. 05, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, will hold a conference call on Friday, November 12, 2021 at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2021. A press release detailing these results will be issued prior to the call.

ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period.

To access the call, please use the following information:

Participants can register for the conference call by navigating to: https://dpregister.com/sreg/10161532/ef2e0ef568

Please note that registered participants will receive their dial in number upon registration. Pre-registration required fields of information include: name, phone, company, email.

Those without internet access or unable to pre-register may dial in to the conference call by calling:

Please call the conference telephone number 5-10 minutes prior to the start time. Please ask to be joined into the ProPhase Labs, Inc. conference call. An operator will register your name, phone and organization.

The conference call will be broadcast live and available for replay at https://services.choruscall.com/mediaframe/webcast.html?webcastid=ddkWfCfc and via the investor relations section of the Company's website at www.ProPhaseLabs.com.

A replay of the conference call will be available two hours from when the call ends.

About ProPhase Labs

ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. ProPhase Precision Medicine, Inc. focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

ProPhase Diagnostics offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients who may have SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Critical to COVID testing, results are provided in under 24 hours. ProPhase Diagnostics also offers PCR (polymerase chain reaction) testing for Influenzas A and B and RSV; as well as antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

ProPhase Global Healthcare, Inc. was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements^® brand. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.

Investor Contact: 
CORE IR
Jules Abraham
917-885-7378
julesa@coreir.com

Released November 5, 2021